title: Targets, Toxins, and T Cells--a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas.
abstract: The peripheral T cell lymphomas (PTCLs) are a heterogeneous group of neoplasms for which standardized treatment approaches remain elusive. A number of new therapeutic agents have become available, of which monoclonal antibodies (MAbs) represent a powerful tool for targeted treatment of PTCLs. Therapeutic MAbs vary in their structure, targets, and mechanisms of action. Common mechanisms of action include antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, direct apoptosis, blocking of receptors or signaling pathways, delivery of cytotoxic agents to tumor cells, and binding to and blocking biologically active molecules. This review will focus on recent published evidence for the various MAbs used in the treatment of PTCLs. The results overall have been very promising, and the future will see more trials with these antibodies alone and in various therapy combinations, as well as newer ones with novel modifications, conjugates, and targets.
authors.affiliation: Department of Medicine, Division of Oncology, Stanford University, 269 Campus Drive, CCSR 1105, Stanford, CA, 94305, USA. JHebb@Stanford.edu.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Hebb
authors.affiliation: Department of Medicine, Division of Oncology, Stanford University, 269 Campus Drive, CCSR 1105, Stanford, CA, 94305, USA. Kohrt@Stanford.edu.
authors.forename: Holbrook
authors.initials: H
authors.lastname: Kohrt
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal
keywords: Monoclonal antibodies; Peripheral T cell lymphomas; T cell lymphomas